Moreover, improvement in cardiovascular risk factors, including lipid profile and carotid-intima media thickness, with potent GLP-1 RA treatment is well established,36 and may contribute to the reduced risk of MACE, and specifically cerebral infarction, established in our study.37 This evidence concerns the gene GLP1R and cerebral infarction.